Schistosome musculature

Schistosome musculature refers to the complex system of somatic and visceral muscles in parasitic flatworms of the genus Schistosoma, which are the causative agents of schistosomiasis (PMID: 16569296). This musculature is essential for the parasite's survival, facilitating locomotion, attachment to host blood vessel walls via suckers, feeding, and the maintenance of the characteristic pairing between male and female worms (PMID: 37498881). The muscle system is a primary therapeutic target for anthelmintic drugs, most notably Praziquantel, which is the gold standard treatment for schistosomiasis (PMID: 31243165). Praziquantel acts by inducing a rapid influx of calcium ions into the muscle cells, leading to immediate spastic paralysis and subsequent tegumental damage, which allows the host's immune system to clear the parasites (PMID: 16569296). Key molecular components within this system that serve as drug targets include voltage-gated calcium channels, specifically the beta subunit, and transient receptor potential (TRP) channels such as Sm.TRPMPZQ (PMID: 11585919, PMID: 31243165). Other targets within the neuromuscular system include acetylcholinesterase and various G protein-coupled receptors for neurotransmitters like serotonin and dopamine (PMID: 19501138). Disruption of these targets leads to loss of motor control, detachment from the host vasculature, and eventual death of the worm. Despite its importance, the musculature presents challenges for drug development, including potential cross-reactivity with host muscle proteins and the relative insensitivity of juvenile schistosomes to current treatments (PMID: 37498881).

Other names

Schistosome muscle systemSchistosome somatic musculatureSchistosome neuromuscular system

Induction of rapid spastic paralysis through increased calcium permeability (via voltage-gated calcium channels or TRP channels) or inhibition of neurotransmitter degradation (acetylcholinesterase).